Immune checkpoint blockade (ICB) evokes antitumor immunity through the reinvigoration of T cell responses. T cell differentiation status controls response, with less differentiated cells having an enhanced capacity to proliferate after ICB. Given that conventional type 1 dendritic cells (cDC1) maintain precursor exhausted T cells (TPEX), we hypothesized that expansion of cDC1s with Flt3L could enhance responses to ICB. Here we show that treatment with Fms-related tyrosine kinase 3 ligand (Flt3L) expands CD62L+SLAMF6+CD8+ T cells in the tumor through a mechanism that requires XCR1+ dendritic cells to traffic to the tumor-draining lymph node. The combination of Flt3L and anti-CTLA-4 enhanced therapeutic responses. Combination therapy is associated with the emergence of a CD8+ T cell subset characterized by the expression of Il21r and oligoclonal expansion of CD8+ T cells within tumors through a mechanism that is dependent on lymph node egress.
CD8+ T cell exhaustion is a regulatory state triggered by chronic antigen stimulation in both cancer and persistent infection. The less differentiated stem-like sub-populations of exhausted T cells have been heavily studied given their importance to the efficacy of current immunotherapies. While the transcription factor TCF1 is both necessary and sufficient for formation and maintenance of these stem-like populations, it remains unclear whether TCF1 can actively de-differentiate more terminally exhausted subsets back into a stem-like state. To address this question, here we utilize and optimize a high efficiency CRISPR knock-in methodology, compatible with mouse in vivo exhaustion models, to engineer T cells that either constitutively over-express TCF1, or conditionally over-express TCF1 following differentiation of the cells into a CX3CR1+ intermediate-exhausted state. Strikingly, we find that only constitutive, and not conditional, TCF1 over-expression can increase the size of the stem-like T cell pool. Thus, while TCF1 can slow stem-like T cell differentiation, it is insufficient to revert more differentiated cells back into a stem-like state.
Armoring chimeric antigen receptor (CAR) T cells with cytokines is a promising strategy to overcome immunosuppression in solid tumors, but is frequently limited by toxicities arising from systemic cytokine expression. Previously, we developed a CRISPR/Cas9-based engineering strategy that leverages the regulatory mechanisms of endogenous genes to enable tumor-restricted transgene expression in CAR T cells. Herein, we describe a next-generation strategy that preserves endogenous target gene expression and retains regulatory architecture in the 3’ untranslated region (UTR) during transgene integration. At the RGS16 locus, this strategy markedly tightened transgene activation, resulting in highly tumor-localized delivery of IL-12 and IL-2 across both xenogeneic and syngeneic models. Mechanistically, this enhanced precision was mediated by retention of the 3’UTR. This regulatory feature was conserved across additional tumor-specific loci, supporting 3′UTR-mediated regulation as a broadly applicable mechanism for refining transgene control. Together, these findings establish a versatile engineering platform for the precise and safe armoring of CAR T cells in solid tumors.